Key Clinical Trials in Treating Diabetic Retinopathy

Understanding the evidence behind diabetic retinopathy treatment decisions is crucial for providing optimal patient care. Three landmark clinical trials published by the Diabetic Retinopathy Clinical Research Network, Protocols S, T, and V, have fundamentally shaped how we approach diabetic retinopathy and diabetic macular edema (DME) treatment today.

Protocol S: Revolutionizing Proliferative Diabetic Retinopathy Treatment

Click here for the link to the protocol

Design

Protocol S was a groundbreaking randomized trial that compared monthly ranibizumab injections (0.5 mg) with standard panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR) over two years. The study allowed injections to be deferred if neovascularization remained stable, providing a more flexible treatment approach.

Key Findings at 2 Years

• Visual acuity outcomes: Ranibizumab proved noninferior to PRP for maintaining vision
• Superior visual improvements: Patients receiving ranibizumab gained an average of 2.8 letters compared to only 0.2 letters with PRP
• Fewer side effects: The anti-VEGF group experienced less peripheral visual field loss, reduced rates of diabetic macular edema, and fewer vitrectomy procedures

Long-term Results (5 Years)

• Both treatment groups maintained good visual acuity over the long term
• Severe vision loss remained rare in both groups
• The ranibizumab group continued to show advantages with less visual field loss and fewer DME cases
• However, the study highlighted potential compliance challenges due to the need for frequent injections

Clinical Impact

Protocol S transformed PDR management by providing treatment flexibility. Reliable patients who can commit to regular follow-up may benefit from anti-VEGF therapy, while others may still be better candidates for PRP. Many clinicians now favor combined therapy approaches for more durable disease control.

Protocol T: Comparing Anti-VEGF Agents for Diabetic Macular Edema

Click here for the link to the protocol

Design

Protocol T conducted a head-to-head comparison of three anti-VEGF agents, aflibercept, bevacizumab, and ranibizumab, in patients with center-involved DME and visual acuity ranging from 20/32 to 20/320. The study used monthly retreatment in year one and pro re nata (PRN) dosing in year two.

Key Findings at 2 Years

• Overall efficacy: All three medications improved visual acuity
• Baseline vision matters: For patients with baseline visual acuity of 20/50 or worse, aflibercept produced significantly greater visual gains
• Mild impairment: In cases with milder initial visual impairment (20/32 to 20/40), outcomes were similar across all three agents

Five-Year Follow-up

• Mean visual acuity remained approximately 7 letters better than baseline
• There was a decline of about 5 letters between years 2 and 5
• Regular anti-VEGF treatment was tapered after the trial, with most patients receiving only about 4 injections between years 2-5
• No long-term differences emerged among the three drugs when post-trial treatments were not standardized

Clinical Impact

Protocol T established that aflibercept should be the preferred choice for patients with worse baseline visual acuity. However, cost-effectiveness remains an important consideration, as bevacizumab is significantly less expensive while being only slightly less potent than the other options.

Protocol V: Managing Good Vision with Center-Involved DME

Click here for the link to the protocol

Design

Protocol V addressed a common clinical dilemma: whether to treat center-involving DME immediately when patients still have good vision (20/25 or better). The study compared immediate treatment with aflibercept, focal/grid laser therapy, or observation alone, with rescue treatment allowed for vision decline.

Key Findings at 2 Years

• Similar vision loss rates: Vision loss of 5 letters or more occurred in approximately 16%, 17%, and 19% of the aflibercept, laser, and observation groups, respectively—differences that were not statistically significant
• Excellent outcomes across groups: After 2 years, mean visual acuity was approximately 20/20 across all treatment groups
• Rescue treatment utilization: Many patients in the laser (25%) and observation (34%) groups eventually required rescue anti-VEGF injections

Clinical Impact

Protocol V demonstrated that it's reasonable to initially observe asymptomatic center-involved DME with close monitoring, provided patients are reliable and can commit to regular follow-up visits. This approach requires careful patient selection due to the risk of vision decline if monitoring is inadequate.

Summary: Evidence-Based Treatment Decisions